CVS Health Corporation (NYSE:CVS) updated its fourth quarter earnings guidance on Monday. The company provided earnings per share guidance of $1.88-1.92 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.91.

Several equities analysts have recently commented on the company. Robert W. Baird reaffirmed a hold rating and issued a $77.00 target price on shares of CVS Health Corporation in a research report on Friday, October 27th. Cowen and Company set a $86.00 price target on CVS Health Corporation and gave the company a buy rating in a research note on Sunday, October 29th. BidaskClub upgraded CVS Health Corporation from a sell rating to a hold rating in a research note on Wednesday, August 2nd. TheStreet cut CVS Health Corporation from a b- rating to a c+ rating in a research note on Tuesday, October 31st. Finally, Citigroup Inc. dropped their price target on CVS Health Corporation from $87.00 to $74.00 and set a neutral rating for the company in a research note on Friday. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fifteen have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $87.33.

CVS Health Corporation (NYSE:CVS) opened at $67.50 on Monday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.09 and a quick ratio of 0.56. The firm has a market cap of $70,400.00, a P/E ratio of 11.84, a price-to-earnings-growth ratio of 1.26 and a beta of 0.86. CVS Health Corporation has a 52-week low of $68.01 and a 52-week high of $84.72.

CVS Health Corporation (NYSE:CVS) last posted its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.49 by $0.01. The company had revenue of $46.18 billion during the quarter, compared to analysts’ expectations of $46.17 billion. CVS Health Corporation had a net margin of 2.93% and a return on equity of 17.47%. CVS Health Corporation’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period last year, the company posted $1.64 earnings per share. sell-side analysts predict that CVS Health Corporation will post 5.88 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, November 3rd. Stockholders of record on Tuesday, October 24th were issued a $0.50 dividend. The ex-dividend date of this dividend was Monday, October 23rd. This represents a $2.00 annualized dividend and a dividend yield of 2.96%. CVS Health Corporation’s dividend payout ratio (DPR) is presently 39.84%.

In other news, EVP Thomas M. Moriarty sold 20,547 shares of CVS Health Corporation stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $81.17, for a total value of $1,667,799.99. Following the transaction, the executive vice president now owns 43,178 shares of the company’s stock, valued at approximately $3,504,758.26. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO David M. Denton sold 237,078 shares of CVS Health Corporation stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $79.65, for a total transaction of $18,883,262.70. Following the completion of the transaction, the chief financial officer now directly owns 141,096 shares in the company, valued at approximately $11,238,296.40. The disclosure for this sale can be found here. Insiders sold a total of 716,625 shares of company stock valued at $58,318,431 in the last 90 days. Company insiders own 0.61% of the company’s stock.

WARNING: This article was reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.watchlistnews.com/cvs-health-corporation-cvs-releases-q4-earnings-guidance-2/1682708.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in CVS. Fieldpoint Private Securities LLC lifted its stake in CVS Health Corporation by 333.3% during the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after acquiring an additional 1,000 shares during the period. Optimum Investment Advisors raised its position in CVS Health Corporation by 20.0% during the second quarter. Optimum Investment Advisors now owns 3,444 shares of the pharmacy operator’s stock worth $277,000 after acquiring an additional 573 shares during the period. Bluefin Trading LLC acquired a new position in CVS Health Corporation during the second quarter worth $298,000. Keel Point LLC raised its position in CVS Health Corporation by 16.0% during the second quarter. Keel Point LLC now owns 3,824 shares of the pharmacy operator’s stock worth $308,000 after acquiring an additional 528 shares during the period. Finally, Wafra Investment Advisory Group Inc. NY purchased a new stake in shares of CVS Health Corporation during the second quarter worth $507,000. Institutional investors and hedge funds own 81.46% of the company’s stock.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Earnings History and Estimates for CVS Health Corporation (NYSE:CVS)

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.